Hims & Hers Health and the Great GLP-1 Cleanup

If you’ve been watching Hims & Hers Health, Inc., you’ve seen the vibe shift.

For most of its life as a public company, Hims & Hers (HIMS) has been the internet’s clean, well-designed shortcut to the kinds of healthcare people actually procrastinate on: hair loss, acne, erectile dysfunction, anxiety, and now weight loss. The pitch is simple: stop making healthcare a scavenger hunt. Do it on your phone, get a plan, get the meds, move on with your life.

Then GLP-1s happened. And Hims wandered into the messiest room in modern healthcare.

What just changed

In early February 2026, Hims said it would launch a cheaper, off-brand version of Novo Nordisk’s Wegovy pill (the latest twist in America’s weight-loss gold rush). Novo Nordisk didn’t exactly send a fruit basket—publicly pushing back and signaling legal action.

Days later, by February 9, 2026, Hims had already backed away from that plan after U.S. health officials asked for an investigation into whether the company’s move crossed legal lines.

Fast-forward to March 9, 2026, and the storyline flips: Novo Nordisk announced an agreement with Hims & Hers that expands access to its FDA-approved semaglutide meds—Ozempic and Wegovy—through Hims’ platform. In the same moment, Hims said it would stop promoting compounded GLP-1 ads and would limit compounded semaglutide to select clinical cases.

In other words: Hims is moving from “we can source a workaround” to “we’ll be a front door for the real thing.” That’s a big deal, because weight loss is not a side quest for Hims anymore—it’s a brand-defining category.

Why this matters beyond the headline

Here’s the uncomfortable truth about GLP-1s: the demand is real, the outcomes can be dramatic, and the system delivering them is chaotic. Shortages, self-pay pricing, telehealth on-ramps, compounding pharmacies, and regulators trying to catch up—all of it has made the category feel like a startup scene trapped inside a medical one.

Hims’ broader bet is that people want a consistent “healthcare home base” that doesn’t feel like a hospital waiting room. But to be that home base at scale, you need trust—especially when you’re dealing with drugs that are both expensive and politically visible.

That’s why this agreement with Novo Nordisk (NVO) reads like more than a distribution update. It’s a legitimacy play. Hims gets to keep its weight-loss momentum while stepping away from the kind of gray-zone marketing that invites regulators, lawsuits, and reputational damage.

The business context investors should actually care about

On February 23, 2026, Hims reported fourth-quarter and full-year 2025 results. The company posted $20.6 million in net income in Q4 2025 and $128 million in net income for full-year 2025. It also ended 2025 with $929 million in cash, short-term, and long-term investments.

But the most telling detail wasn’t a single line item—it was Hims changing how it talks about its customer engine. The company said it expects to stop reporting its prior subscriber metric beginning with the quarter ending March 31, 2026, and to lean into a new measure: monthly revenue per average subscriber.

That’s a quiet signal that Hims thinks the market is ready to judge it less like a “how many users?” app and more like a “how valuable are these relationships?” platform.

And GLP-1s are exactly the kind of category that can raise that value—if Hims can keep patients engaged, supported, and safely supplied. The catch is that selling “the real thing” (branded meds) can also mean different economics than selling compounded alternatives. So the next chapter is about execution: can Hims keep the convenience and personalization people love while operating inside the tighter boundaries of branded pharma?

This isn’t about hype. It’s about whether Hims can mature without losing the product instincts that made it popular in the first place.